JP2012507270A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507270A5
JP2012507270A5 JP2011533718A JP2011533718A JP2012507270A5 JP 2012507270 A5 JP2012507270 A5 JP 2012507270A5 JP 2011533718 A JP2011533718 A JP 2011533718A JP 2011533718 A JP2011533718 A JP 2011533718A JP 2012507270 A5 JP2012507270 A5 JP 2012507270A5
Authority
JP
Japan
Prior art keywords
rad35
bioreactor
cells
perfusion system
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011533718A
Other languages
English (en)
Japanese (ja)
Other versions
JP5770633B2 (ja
JP2012507270A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/064265 external-priority patent/WO2010060719A1/en
Publication of JP2012507270A publication Critical patent/JP2012507270A/ja
Publication of JP2012507270A5 publication Critical patent/JP2012507270A5/ja
Application granted granted Critical
Publication of JP5770633B2 publication Critical patent/JP5770633B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011533718A 2008-11-03 2009-10-29 アデノウイルスベクターの産生方法 Expired - Fee Related JP5770633B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19812208P 2008-11-03 2008-11-03
EP08168181 2008-11-03
US61/198,122 2008-11-03
EP08168181.9 2008-11-03
PCT/EP2009/064265 WO2010060719A1 (en) 2008-11-03 2009-10-29 Method for the production of adenoviral vectors

Publications (3)

Publication Number Publication Date
JP2012507270A JP2012507270A (ja) 2012-03-29
JP2012507270A5 true JP2012507270A5 (enExample) 2012-12-13
JP5770633B2 JP5770633B2 (ja) 2015-08-26

Family

ID=40344776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533718A Expired - Fee Related JP5770633B2 (ja) 2008-11-03 2009-10-29 アデノウイルスベクターの産生方法

Country Status (15)

Country Link
US (1) US10041049B2 (enExample)
EP (1) EP2350268B1 (enExample)
JP (1) JP5770633B2 (enExample)
KR (1) KR101504392B1 (enExample)
CN (1) CN102203242B (enExample)
AU (1) AU2009319254B2 (enExample)
BR (1) BRPI0921651A2 (enExample)
CA (1) CA2742474C (enExample)
DK (1) DK2350268T3 (enExample)
EA (1) EA019928B1 (enExample)
ES (1) ES2532015T3 (enExample)
MX (1) MX2011004292A (enExample)
NZ (1) NZ593235A (enExample)
PL (1) PL2350268T3 (enExample)
WO (1) WO2010060719A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2742474C (en) 2008-11-03 2016-05-31 Crucell Holland B.V. Method for the production of adenoviral vectors
KR101805938B1 (ko) 2009-10-15 2018-01-10 얀센 백신스 앤드 프리벤션 비.브이. 고밀도 세포 배양액에서 아데노바이러스의 정제 방법
AU2010305765B2 (en) 2009-10-15 2015-07-02 Crucell Holland B.V. Method for the purification of adenovirus particles
JP5250155B2 (ja) * 2010-02-15 2013-07-31 クルセル ホランド ベー ヴェー Ａｄ２６アデノウイルスベクターの製造方法
US8771709B2 (en) 2010-09-20 2014-07-08 Crucell Holland B.V. Therapeutic vaccination against active Tuberculosis
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
US8845902B2 (en) 2011-02-10 2014-09-30 Crucell Holland B.V. Pneumatic alternating pressure membrane cell separation system
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
CA2864956C (en) 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
AP2014007993A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
SG11201508567XA (en) 2013-04-25 2015-11-27 Crucell Holland Bv Stabilized soluble prefusion rsv f polypeptides
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
US10392603B2 (en) * 2013-08-30 2019-08-27 The Chemo-Sero-Therapeutic Research Institute Method of viral purification
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2016071306A1 (en) 2014-11-04 2016-05-12 Crucell Holland B.V. Therapeutic hpv16 vaccines
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
US9663766B2 (en) 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
MY195389A (en) 2015-08-20 2023-01-18 Janssen Vaccines & Prevention Bv Therapeutic HPV18 Vaccines
CN109069612A (zh) 2016-04-05 2018-12-21 扬森疫苗与预防公司 针对rsv的疫苗
EP3808374A1 (en) 2016-04-05 2021-04-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f proteins for use in the prophylaxis of rsv infection
WO2017180724A1 (en) * 2016-04-12 2017-10-19 Artemis Biosystems, Inc. Perfusion filtration systems
US10517944B2 (en) 2016-05-02 2019-12-31 Janssen Vaccines & Prevention B.V. Therapeutic HPV vaccine combinations
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
PE20190110A1 (es) 2016-05-30 2019-01-15 Janssen Vaccines And Prevention B V Proteinas f de prefusion del vrs estabilizadas
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
EP3484506A1 (en) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv vaccines
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
BR112020004143A2 (pt) 2017-09-15 2020-09-01 Janssen Vaccines & Prevention B.V. método para a indução segura de imunidade contra vírus sincicial respiratório (rsv)
EP3704256A1 (en) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
AU2018359492B2 (en) 2017-10-31 2023-12-14 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
MX2020004487A (es) 2017-10-31 2020-08-13 Janssen Vaccines & Prevention Bv Adenovirus y usos de estos.
US11236361B2 (en) 2017-10-31 2022-02-01 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
IL321479A (en) * 2017-12-11 2025-08-01 Amgen Inc Lengthy manufacturing process for bispecific antibody products
CN110317832B (zh) 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
CN110317791A (zh) 2018-03-29 2019-10-11 西比曼生物科技（香港）有限公司 Gmp级无血清悬浮细胞大规模生产慢病毒的方法
WO2019209632A1 (en) 2018-04-24 2019-10-31 Merck Sharp & Dohme Corp. Scalable chromatography process for purification of human cytomegalovirus
PH12021550974A1 (en) 2018-11-13 2022-05-02 Janssen Vaccines & Prevention Bv Stablized pre-fusion rsv f proteins
BR112022000061A2 (pt) * 2019-07-01 2022-05-24 Ology Bioservices Inc Método para o cultivo de células aderentes em um bioreator multiparalelo
CN116096732A (zh) 2020-01-31 2023-05-09 贝斯以色列护理医疗中心有限公司 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
US20240197859A1 (en) 2021-04-01 2024-06-20 Janssen Vaccines & Prevention B.V. Stabilized Pre-Fusion PIV3 F Proteins
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4448802A1 (en) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
EP4590689A1 (en) 2022-09-23 2025-07-30 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
EP4590690A1 (en) 2022-09-23 2025-07-30 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
CR20250116A (es) 2022-10-06 2025-05-05 Msd Int Business Gmbh Proteína f de piv3 de prefusión estabilizadas

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04241381A (ja) 1991-01-16 1992-08-28 Brother Ind Ltd 電子学習機
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
WO1995034671A1 (en) 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびａａｖの精製
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
AU732703B2 (en) 1996-11-20 2001-04-26 Crucell Holland B.V. An improved method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
CA2723040A1 (en) 1998-02-17 1999-08-19 Schering Corporation Compositions comprising viruses and methods for concentrating virus preparations
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
DE69927013T2 (de) 1998-04-22 2006-06-29 Genvec, Inc. Effiziente reinigung von adenovirus
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20040043489A1 (en) 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
WO2000029024A1 (en) 1998-11-16 2000-05-25 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
CA2356373A1 (fr) 1998-12-31 2000-07-13 Aventis Pharma S.A. Methode de separation de particules virales
ATE332364T1 (de) 1999-02-22 2006-07-15 Transgene Sa Verfahren zur gewinnung von purifizierter virenzuammensetzung
EP1816204B1 (en) 1999-05-17 2010-10-20 Crucell Holland B.V. Recombinant Adenovirus of the Ad26 serotype
US20050232900A1 (en) 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
JP5118798B2 (ja) 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
WO2003049763A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for the preservation of viruses
WO2003062400A2 (en) 2002-01-24 2003-07-31 The Scripps Research Institute Fiber shaft modifications for efficient targeting
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
ES2335657T3 (es) 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
WO2004001032A2 (en) 2002-04-25 2003-12-31 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
WO2003097797A2 (en) 2002-05-14 2003-11-27 Merck & Co., Inc. Methods of adenovirus purification
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
NZ539813A (en) 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
WO2004099422A2 (en) 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
EP1670925B1 (en) 2003-10-02 2013-05-01 Crucell Holland B.V. Packaging cells for recombinant adenovirus
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
CN104593277A (zh) * 2004-03-05 2015-05-06 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
CA2569405C (en) 2004-06-04 2011-05-03 Xcellerex, Inc. Disposable bioreactor systems and methods
US7741099B2 (en) 2004-10-13 2010-06-22 Beth Israel Deaconess Medical Center Inc. Adenoviral vectors and uses thereof
EA016648B1 (ru) 2004-10-14 2012-06-29 Круселл Холланд Б.В. Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии
NZ555907A (en) 2004-11-16 2009-12-24 Aeras Global Tb Vaccine Found Multivalent vaccines comprising recombinant viral vectors
JP2008538894A (ja) 2005-02-11 2008-11-13 メルク エンド カムパニー インコーポレーテッド アデノウイルス血清型２６ベクター、核酸およびそれにより製造されたウイルス
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
KR20080052512A (ko) 2005-05-23 2008-06-11 박신, 인크. 아데노바이러스-무함유 재조합 아데노바이러스 벡터의 급속생산
US20100115874A1 (en) 2005-07-22 2010-05-13 Pergo (Europe) Ab Flooring system including a dry glue
JP2009512421A (ja) 2005-08-15 2009-03-26 ヴァクシン インコーポレイテッド 非複製性ベクターワクチン投与による鳥類への免疫方法
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
EP1998804B1 (en) 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
US9592282B2 (en) 2006-07-18 2017-03-14 Glaxosmithkline Biologicals Sa Vaccines for malaria
HUE031411T2 (en) 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
US9109193B2 (en) 2007-07-30 2015-08-18 Ge Healthcare Bio-Sciences Corp. Continuous perfusion bioreactor system
CN101855371A (zh) 2007-11-14 2010-10-06 张惇杰 制备用于锂离子电池应用的空气敏感性电极材料的方法和装置
WO2009117134A2 (en) 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
CA2742474C (en) 2008-11-03 2016-05-31 Crucell Holland B.V. Method for the production of adenoviral vectors
JP5845178B2 (ja) 2009-07-16 2016-01-20 クルセル ホランド ベー ヴェー ワクチン生産のためのポリオウイルスの高力価での生産
KR101805938B1 (ko) 2009-10-15 2018-01-10 얀센 백신스 앤드 프리벤션 비.브이. 고밀도 세포 배양액에서 아데노바이러스의 정제 방법
JP5250155B2 (ja) 2010-02-15 2013-07-31 クルセル ホランド ベー ヴェー Ａｄ２６アデノウイルスベクターの製造方法
US20120315696A1 (en) 2010-02-15 2012-12-13 Alfred Luitjens METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS

Similar Documents

Publication Publication Date Title
JP2012507270A5 (enExample)
NZ593235A (en) Method for the production of recombinant adenovirus serotype 35
JP2014521353A5 (enExample)
JP2019516410A5 (enExample)
CN102762721B (zh) 用于生产Ad26腺病毒载体的方法
Feuchtinger et al. Adenovirus infection after allogeneic stem cell transplantation
JP2011125348A5 (enExample)
JP2009034115A5 (enExample)
JP2004505623A5 (enExample)
WO2020076820A3 (en) Compositions and methods for preparing viral vectors
CN103732236A (zh) 用于生产痘苗病毒的方法和组合物
Cornax et al. Newcastle disease virus fusion and haemagglutinin-neuraminidase proteins contribute to its macrophage host range
JP5980947B2 (ja) 高感染価のパルボウイルスの生産方法
JP2013515473A5 (enExample)
Duffy et al. Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56
Kimura et al. Deletion of Viral microRNAs in the Oncogenesis of Epstein–Barr Virus-Associated Lymphoma
JP2013538588A5 (enExample)
Ross et al. Construction and characterization of adenovirus vectors
JP2008508899A5 (enExample)
WO2024114733A1 (zh) 一种分离纯化cvb1的方法
CN116200348A (zh) 一种适应Vero细胞的柯萨奇病毒A10型毒株的构建方法及其应用
CN114107389A (zh) 表达非洲猪瘟病毒b602l-b646l蛋白的重组腺病毒及构建方法
CN1552851A (zh) Sars冠状病毒的假病毒及其制备方法和用途
CN102533657B (zh) 一种人41型腺病毒(Ad41)包装细胞株及其应用
CN103642760B (zh) 一种制备柯萨奇a16型病毒完整实心颗粒的方法